STOCK TITAN

Metagenomi Therapeutics (MGX) Stock Price, News & Analysis

MGX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
33 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+13.8% close of December 3, 2025
1-year change
-59.3% closing prices, November 13, 2025 to November 13, 2026
1-month change
-24.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a biotechnology company in the healthcare sector that focuses on in vivo genome editing and precision genetic medicines. According to the company, it is developing genetic medicines that aim to be curative by directly editing DNA inside the body using a proprietary gene editing toolbox discovered through metagenomics, the study of genetic material recovered from the natural environment.

The company describes itself as an in vivo genome editing and precision genetic medicines company that is committed to developing curative therapeutics for patients using its proprietary technologies and AI-driven metagenomics platform. Its approach is based on discovering and developing a suite of novel editing tools potentially capable of correcting many types of genetic mutations across the human genome. Metagenomi Therapeutics reports that its genome editing toolbox includes programmable nucleases, base editors, RNA- and DNA-mediated integration systems, CRISPR-associated transposases (CAST), and RNA-Mediated Integration Systems (RIGS), as well as ultra-small and compact nucleases designed for in vivo delivery.

The company states that it focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Its lead, wholly owned development program, MGX-001, targets hemophilia A. Metagenomi Therapeutics reports that MGX-001 has demonstrated a preclinical profile potentially competitive with existing treatment options, including targeted genome editing and durable gene expression in a one-time treatment. In non-human primate studies, the company has reported durable and therapeutically relevant factor VIII (FVIII) activity over approximately 19 months and dose range finding data showing curative FVIII activity, informing a proposed clinical dose regimen.

According to company disclosures, MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A by enabling endogenous production of FVIII for hemostatic regulation. The company has also reported that MGX-001 uses a site-specific genome integration system and has shown no identifiable off-target editing in a series of orthogonal assays in preclinical studies.

Beyond hemophilia A, Metagenomi Therapeutics states that it is pursuing additional secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system. The company has reported in vivo proof-of-concept in non-human primates for antithrombin (AT-III) deficiency and is evaluating other secreted protein disorders as potential applications of the same genome integration approach.

The company also highlights partnered cardiometabolic programs. Metagenomi has disclosed a collaboration with Ionis Pharmaceuticals that includes multiple targets in significant cardiometabolic indications. One of these targets is APOC3, where the company has presented preclinical data on CRISPR/Cas-mediated APOC3 knockout as a one-time treatment for severe hypertriglyceridemia. These cardiometabolic programs are described as part of a collaboration wave that includes several targets.

Metagenomi Therapeutics emphasizes that its platform is built on metagenomics and AI-guided discovery. It reports that its metagenomics-derived gene editing toolbox has analyzed billions of proteins and is designed to identify compact and efficient gene editing systems. The company has presented data on compact Type II and Type V nucleases for extrahepatic gene editing, including in the central nervous system (CNS), and on a Type V-K CAST system engineered for site-specific integration of large therapeutic genes in primary mammalian cells. According to the company, these tools support full spectrum gene editing, from small edits and knockdown to large gene integrations.

In its corporate updates, Metagenomi Therapeutics has described a strategic pipeline prioritization that focuses resources on later-stage preclinical assets and its most advanced gene-editing capabilities. This includes concentrating on MGX-001 in hemophilia A, additional secreted protein disorders that use the MGX-001 integration system, and cardiometabolic indications under its collaboration with Ionis. The company has also disclosed organizational changes and a name change from Metagenomi, Inc. to Metagenomi Therapeutics, Inc., stating that the new name reflects a strategic evolution focused on later-stage preclinical assets and its signature gene-editing capabilities.

Metagenomi Therapeutics is headquartered in Emeryville, California, as indicated in its press releases. The company describes itself as an emerging growth company under U.S. securities regulations and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including quarterly reports on Form 10-Q and current reports on Form 8-K that provide financial results, pipeline updates, and corporate developments.

According to its public statements, Metagenomi Therapeutics intends to continue expanding its pipeline by leveraging its proprietary editing capabilities in site-specific deletion, integration, and correction. The company’s disclosures emphasize applications in indications where disease biology is well characterized and where genome editing approaches can be aligned with established regulatory pathways.

Business focus and technology

Metagenomi Therapeutics’ business centers on discovering and developing genome editing tools and applying them to in vivo therapies. The company highlights several technology components:

  • A metagenomics-based discovery engine that identifies novel gene editing systems from natural microbial diversity.
  • An AI-driven platform used to systematically identify and optimize compact CRISPR systems for therapeutic genome editing.
  • A gene editing toolbox that includes programmable nucleases, base editors, CRISPR-associated transposases (CAST), RNA- and DNA-mediated integration systems, and RNA-Mediated Integration Systems (RIGS).
  • Compact and ultra-compact nucleases designed for delivery via adeno-associated virus (AAV) or other vectors, including applications in extrahepatic tissues and the central nervous system.

These capabilities are described by the company as enabling targeted gene knockdown, correction, and large gene integration, with potential applications across multiple genetic diseases.

Therapeutic pipeline

Based on company disclosures, Metagenomi Therapeutics’ pipeline includes:

  • MGX-001 (Hemophilia A): A wholly owned, in vivo genome editing program designed as a one-time treatment for hemophilia A, aiming for durable FVIII expression and life-long protection from bleeding and joint damage.
  • Secreted protein deficiencies: Additional wholly owned programs that leverage the MGX-001 site-specific genome integration system, including proof-of-concept work in antithrombin (AT-III) deficiency and evaluation of other secreted protein disorders.
  • Cardiometabolic indications: Partnered assets targeting cardiometabolic diseases, including APOC3 as a collaboration target with Ionis Pharmaceuticals, with preclinical data presented on CRISPR/Cas-mediated APOC3 knockout.

The company has reported that it prioritizes later-stage preclinical programs and indications with clearly defined regulatory and clinical development pathways.

Regulatory and public company status

Metagenomi Therapeutics, Inc. trades on Nasdaq under the ticker symbol MGX. SEC filings such as Form 8-K current reports show that the company provides regular updates on financial results, clinical and preclinical data, and corporate presentations. In these filings, Metagenomi identifies itself as an emerging growth company and notes that certain information furnished under Items 2.02 and 7.01 of Form 8-K is not deemed filed for purposes of Section 18 of the Exchange Act.

Stock Performance

$0.6917
-3.12%
-0.0223
Last updated: November 13, 2026 at 16:00
-59.3%
Performance 1 year
$26.2M

Metagenomi Therapeutics (MGX) closed at $0.6917 on November 13, 2026. Over the past 12 months, the price has lost 59.3%.

See what a $1,000 investment in MGX would be worth today

Average down calculator for MGX

MGX Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Metagenomi Therapeutics has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, clinical trial. View all MGX news →

Insider Radar

Net Buyers
90-Day Summary
20,000
Shares Bought
4,409
Shares Sold
5
Transactions
Most Recent Transaction
Reid Laurence (Director) bought 20,000 shares at an average of $1.17 on September 9, 2026

Insider buying activity at Metagenomi Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Metagenomi Therapeutics generated $25.2M in revenue in FY2025, operating income reached -$96.0M, and net income was -$87.9M. Diluted earnings per share stood at -$2.36. The company generated -$88.9M in operating cash flow. The current ratio was 7.22, measuring current assets divided by current liabilities.

$25.2M
Revenue (FY2025)
-$87.9M
Net Income (FY2025)
-$88.9M
Operating Cash Flow

Upcoming Events

NOV
18
November 18, 2026 Marketing

Jefferies fireside chat

CEO Jian Irish to appear in London, UK at Jefferies Global Healthcare Conference on Nov 18 at 12:00pm ET; live webcast on company site.
DEC
14
December 14, 2026 Clinical

ASH oral presentation

Oral presentation at ASH in New Orleans on Dec 14, 2026 at 2:45pm CT (CST) covering MGX-001 preclinical efficacy, safety, durability.
YEAR
2027
2027 Clinical

First-in-human study start

Initiation of first-in-human (FIH) studies for MGX-001, timing subject to IND clearance.
H1
2027
H1 2027 Clinical

INTEGR8 trial start

Start of Phase 1/2 INTEGR8 trial for MGX-001 in the U.S.; FDA cleared human testing; expansion needs additional clearances.
YEAR
2027
2027 Clinical

Global clinical trial start

Planned initiation of a global MGX-001 clinical trial in 2027, contingent on regulatory clearance and approvals across jurisdictions.
YEAR
2027
2027 Clinical

Clinical trial initiation

Potential initiation of first clinical trial for MGX-001 sometime in 2027, contingent on IND clearance and regulatory approval.
YEAR
2027
2027 Clinical

MGX-001 clinical trials start

Clinical trials for MGX-001 expected in 2027 pending IND clearance; timing subject to regulatory acceptance and scheduling.
H2
2027
H2 2027 Clinical

Initial safety data

Release of initial safety, tolerability and Factor VIII activity data from INTEGR8 Phase 1/2 trial (MGX-001) in H2 2027.
Q4
2027
Q4 2027 Financial

Cash runway through Q4

Company anticipates cash runway into Q4 2027; potential financing may be needed thereafter.

Metagenomi Therapeutics has 9 upcoming scheduled events. The next event, "Jefferies fireside chat", is scheduled for November 18, 2026 (in 3 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the MGX stock price.

Short Interest History

Last 12 Months

Short interest in Metagenomi Therapeutics (MGX) currently stands at 1.3 million shares, up 2.9% from the previous reporting period, representing 4.4% of the float. Since November 2025, short interest has decreased by 17.4%.

Days to Cover History

Last 12 Months

Days to cover for Metagenomi Therapeutics (MGX) currently stands at 11.1 days, up 77.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 149.6%. Across the settlements charted above, it has ranged from 4.5 to 12.1 days.

MGX Company Profile & Sector Positioning

Metagenomi Therapeutics (MGX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MGX often look at related companies in the same sector, including Evaxion A/S (EVAX), Polyrizon Ltd. (PLRZ), EyePoint, Inc. (EYPT), Edesa Biotech, Inc. (EDSA), and Adicet Bio, Inc. (ACET). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MGX's relative position within its industry.

Frequently Asked Questions

The current stock price of Metagenomi Therapeutics (MGX) is $0.6917 as of November 13, 2026.

The market cap of Metagenomi Therapeutics (MGX) is approximately $26.2M. Learn more about what market capitalization means .

The FY2025 revenue of Metagenomi Therapeutics (MGX) is $25.2M, from its most recent completed fiscal year.

The FY2025 net income of Metagenomi Therapeutics (MGX) is -$87.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Metagenomi Therapeutics (MGX) is -$2.36 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Metagenomi Therapeutics (MGX) is -$88.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Metagenomi Therapeutics (MGX), current assets divided by current liabilities, was 7.22 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Metagenomi Therapeutics (MGX) is -$96.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a biotechnology company focused on in vivo genome editing and precision genetic medicines. It uses a metagenomics-based and AI-driven platform to discover and develop novel gene editing tools intended to create potentially curative treatments for genetic diseases.

The company’s pipeline centers on in vivo genome editing programs, with its lead, wholly owned program MGX-001 targeting hemophilia A. It also pursues additional secreted protein deficiencies and partnered cardiometabolic indications that use its proprietary gene editing systems.

MGX-001 is designed as a one-time in vivo genome editing treatment that enables endogenous production of factor VIII (FVIII) for hemostatic regulation. Metagenomi Therapeutics reports that preclinical non-human primate studies have shown durable and therapeutically relevant FVIII activity, supporting advancement toward clinical development.

According to company descriptions, the toolbox includes programmable nucleases, base editors, RNA- and DNA-mediated integration systems, CRISPR-associated transposases (CAST), RNA-Mediated Integration Systems (RIGS), and compact and ultra-compact CRISPR nucleases designed for in vivo delivery.

Metagenomi Therapeutics states that it was founded on the science of metagenomics, which involves studying genetic material recovered from the natural environment. This approach allows the company to discover novel gene editing systems from microbial diversity and to build a broad genome editing toolbox.

The company reports that it leverages artificial intelligence and machine learning to systematically identify and optimize compact CRISPR systems and other gene editing tools, supporting the design of efficient editors and integration systems for therapeutic applications.

Beyond hemophilia A, Metagenomi Therapeutics is pursuing other secreted protein deficiencies, including antithrombin (AT-III) deficiency, and cardiometabolic diseases through partnered programs that include APOC3 as a target.

Metagenomi Therapeutics has disclosed a collaboration with Ionis Pharmaceuticals that includes multiple targets in significant cardiometabolic indications. Within this collaboration, Metagenomi has presented preclinical data on CRISPR/Cas-mediated APOC3 knockout as a potential one-time treatment for severe hypertriglyceridemia.

Metagenomi Therapeutics identifies Emeryville, California, in the headers of its press releases, indicating that its principal operations are based there.

In its SEC filings, Metagenomi, Inc. identifies itself as an emerging growth company under U.S. securities regulations. This status allows the company to take advantage of certain reduced reporting and compliance requirements during a defined transition period.